Clinical Trial: SWOG S1712

SWOG S1712

Status: Closed

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

S1712 is permanently closed to accrual, effective October 20, 2022.